Generate Biomedicines Picks First Targets To Test Its AI-Based Drug Discovery Revolution
Mutation-Resistant COVID-19 Therapy Is First Candidate
Built with an audacious goal to use AI to unlock the secrets of protein structure and function, Generate Biomedicines believes it is now on the cusp of a drug discovery revolution.
You may also be interested in...
Novo Nordisk Broke UK Rules By ‘Disparaging’ Rival Eli Lilly
The Danish company has once again broken UK industry rules, this time by looking to get the upper hand on its GLP-1 receptor agonist market rival Eli Lilly.
Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.